person · Reporting owner
EcoR1 Capital Fund Qualified, L.P.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | 10% owner | April 17, 2018 | April 18, 2018 |
| Kura Oncology, Inc.KURA · Entity 4871 | 10% owner | December 17, 2018 | January 10, 2019 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | September 19, 2023 | September 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date April 17, 2018 · Filed April 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Call OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $60.00 · Expires 2018-11-16 | Direct | 1,213 |
Reported balance
After 2018-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-17 · Purchase · Acquired 246 · Balance 1,213 |
Kura Oncology, Inc.
Report date December 17, 2018 · Filed January 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,408,097 |
Ending reported balance
After 2018-12-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-12-17 · Sale · Disposed 26,520 · Balance 4,194,209 Row 2 · 2018-12-18 · Purchase · Acquired 78,469 · Balance 4,272,678 Row 3 · 2018-12-19 · Purchase · Acquired 51,879 · Balance 4,324,557 Row 4 · 2018-12-21 · Purchase · Acquired 83,540 · Balance 4,408,097 |
Nuvation Bio Inc.
Report date September 19, 2023 · Filed September 22, 2023 · Amendment
Jointly reported with NODELMAN OLEG, EcoR1 Capital, LLC, EcoR1 Capital Fund, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Notes | 12,674,775 |
Last balance in matching sequence
After 2023-09-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-09-19 · Purchase · Acquired 5,143,000 · Balance 12,504,675 F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 2 · 2023-09-20 · Purchase · Acquired 117,100 · Balance 12,621,775 F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 3 · 2023-09-21 · Purchase · Acquired 53,000 · Balance 12,674,775 F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F2: Qualified Fund is the record holder of these securities.
F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023.
F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023.
F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Panacea Acquisition Corp. II
Report date April 28, 2023 · Filed May 02, 2023
Jointly reported with EcoR1 Panacea Holdings II, LLC, EcoR1 Capital Fund, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Capital, LLC, Biotech Opportunity GP, LLC, NODELMAN OLEG
Section 16 reporting ended · disclosed 2023-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-04-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-04-28 · Disposition to issuer · Disposed 545,000 · Balance 0 F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023.
F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.
aTYR PHARMA INC
Report date May 14, 2018 · Filed May 16, 2018
Section 16 reporting ended · disclosed 2018-05-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-05-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-05-14 · Sale · Disposed 354,791 · Balance 2,854,525 Row 2 · 2018-05-15 · Sale · Disposed 121,294 · Balance 2,733,231 Row 3 · 2018-05-16 · Sale · Disposed 2,733,231 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2023 Filed Sep 22, 2023 15:44 UTC Amendment | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 53,000 | $1.36 | $72,138.30 |
DisclosureSEC source: 0000935836-23-000621 · ownership.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,674,775 F5 · date: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023. F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 15:44 UTC Amendment | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 117,100 | $1.36 | $159,490.20 |
DisclosureSEC source: 0000935836-23-000621 · ownership.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,621,775 F4 · date: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023. F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| September 19, 2023 Filed Sep 22, 2023 15:44 UTC Amendment | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 5,143,000 | $1.26 | $6,460,636.60 |
DisclosureSEC source: 0000935836-23-000621 · ownership.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,504,675 F3 · date: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023. F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| April 28, 2023 Filed May 2, 2023 17:15 UTC | Panacea Acquisition Corp. II PANA · Entity 114006 | Disposition to issuerClass A ordinary shares | 545,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026595 · doc4.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings II, LLC · CIK 0001842055 · Director · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F1 · price: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2 · ownership.direct: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| February 21, 2023 Filed Sep 21, 2023 20:08 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 53,000 | $1.36 | $72,138.30 |
DisclosureSEC source: 0000935836-23-000619 · ownership.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,674,775 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| February 20, 2023 Filed Sep 21, 2023 20:08 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 117,100 | $1.36 | $159,490.20 |
DisclosureSEC source: 0000935836-23-000619 · ownership.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,621,775 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| February 19, 2023 Filed Sep 21, 2023 20:08 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 5,143,000 | $1.26 | $6,460,636.60 |
DisclosureSEC source: 0000935836-23-000619 · ownership.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,504,675 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 21,758 | $7.69 | $167,229.81 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 6 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 4 Disclosed balance after: 1,169,241 F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 163,268 | $7.69 | $1,254,861.52 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 5 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 3 Disclosed balance after: 7,361,675 F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| July 31, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 56,598 | $8.64 | $489,006.72 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 4 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 4 Disclosed balance after: 1,147,483 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| July 31, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 56,598 | $8.64 | $489,006.72 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 3 Disclosed balance after: 7,198,407 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| April 13, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 3,966 | $10.27 | $40,734.79 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 6 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 3 Disclosed balance after: 1,355,625 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| April 13, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 27,534 | $10.27 | $282,801.71 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 5 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 6,990,265 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 16,745 | $9.49 | $158,873.21 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 4 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 3 Disclosed balance after: 1,351,659 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 116,255 | $9.49 | $1,103,004.19 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 6,962,731 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 37,770 | $10.03 | $378,855.76 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 3 Disclosed balance after: 1,334,914 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 262,230 | $10.03 | $2,630,324.24 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 6,846,476 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 15:10 UTC | Panacea Acquisition Corp. II PANA · Entity 114006 | PurchaseClass A ordinary shares | 545,000 | $10.00 | $5,450,000.00 |
DisclosureSEC source: 0001213900-21-021365 · ownership.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings II, LLC · CIK 0001842055 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · CEO and Chairman of the Board EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,000 F1 · ownership.direct: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| March 31, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 151,544 | $10.45 | $1,583,634.80 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 4 Disclosed balance after: 1,145,600 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| March 31, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 151,544 | $10.45 | $1,583,634.80 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 3 Disclosed balance after: 6,735,790 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantWarrant (Right to Buy) · Derivative | 131,333 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 12 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 131,333 Underlying: Class A Common Stock · 131,333 shares Expires not disclosed F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F9 · derivative.expiration_date: 5:00 p.m., New York City time, on February 10, 2026. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantWarrant (Right to Buy) · Derivative | 702,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 11 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 702,000 Underlying: Class A Common Stock · 702,000 shares Expires not disclosed F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F9 · derivative.expiration_date: 5:00 p.m., New York City time, on February 10, 2026. F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantWarrant (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 10 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Liability Company Disclosed balance after: 130,000 Underlying: Class A Common Stock · 130,000 shares Expires not disclosed F10 · price: Warrants included in units purchased in a private placement by EcoR1 Panacea Holdings, LLC for $10.00 per unit in connection with Panacea's initial public offering. Each unit consisted of one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. Upon the closing of the Business Combination, the warrants may be deemed to be derivative securities for purposes of Section 16. F9 · derivative.expiration_date: 5:00 p.m., New York City time, on February 10, 2026. F2 · ownership.nature: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | ConversionClass B Common Stock · Derivative | 2,775,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 9 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Liability Company Disclosed balance after: 0 Underlying: Class A Common Stock · 2,775,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F2 · ownership.nature: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 2,200,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 8 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 2,200,627 F7 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). F8 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Venture Opportunity Fund, LP, which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 515,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 7 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 1,297,144 F7 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 2,365,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 6 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 6,584,246 F7 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 387,265 | $10.00 | $3,872,650.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 5 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 781,265 F6 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination (as defined below), an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 2,112,735 | $10.00 | $21,127,350.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 4 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 4,218,735 F6 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination (as defined below), an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 394,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 394,000 F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 2,106,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 2,106,000 F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | ConversionClass A Common Stock | 2,775,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Liability Company Disclosed balance after: 3,165,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F2 · ownership.nature: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| July 06, 2020 Filed Jul 6, 2020 17:06 UTC | Nuvation Bio Inc. PANA · Entity 4384 | PurchaseClass A common stock | 390,000 | $10.00 | $3,900,000.00 |
DisclosureSEC source: 0001213900-20-016762 · ownership.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings, LLC · CIK 0001816134 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · CEO and Chairman of the Board EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 F1 · shares: The reported shares are included within the 390,000 private placement units of the issuer purchased by EcoR1 Panacea Holdings, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of Class A common stock of the issuer and one-third of one redeemable warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering. F2 · ownership.direct: The reporting owner, the Sponsor, in whose name the securities reported herein are held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| December 21, 2018 Filed Jan 10, 2019 23:32 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 83,540 | $13.16 | $1,099,386.40 |
DisclosureSEC source: 0001567619-19-000984 · doc1.xml · nonDerivative · entry 4 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,408,097 Read SEC document |
| December 19, 2018 Filed Jan 10, 2019 23:32 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 51,879 | $13.84 | $718,005.36 |
DisclosureSEC source: 0001567619-19-000984 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,324,557 Read SEC document |
| December 18, 2018 Filed Jan 10, 2019 23:32 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 78,469 | $13.82 | $1,084,441.58 |
DisclosureSEC source: 0001567619-19-000984 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,272,678 Read SEC document |
| December 17, 2018 Filed Jan 10, 2019 23:32 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 26,520 | $13.20 | $350,064.00 |
DisclosureSEC source: 0001567619-19-000984 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,194,209 Read SEC document |
| December 13, 2018 Filed Dec 13, 2018 23:26 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 25,217 | $13.89 | $350,264.13 |
DisclosureSEC source: 0001567619-18-007956 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,220,729 Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:26 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 15,321 | $13.91 | $213,098.26 |
DisclosureSEC source: 0001567619-18-007956 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,195,512 Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 00:14 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 17,079 | $13.49 | $230,395.71 |
DisclosureSEC source: 0001567619-18-007453 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,180,919 Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 00:14 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 54,645 | $13.08 | $714,756.60 |
DisclosureSEC source: 0001567619-18-007453 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,163,112 Read SEC document |
| December 03, 2018 Filed Dec 7, 2018 00:14 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 48,182 | $13.97 | $673,102.54 |
DisclosureSEC source: 0001567619-18-007453 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,108,467 Read SEC document |
| May 16, 2018 Filed May 16, 2018 21:15 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon Stock | 2,733,231 | $0.81 | $2,216,923.66 |
DisclosureSEC source: 0001140361-18-024271 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:15 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon Stock | 121,294 | $1.43 | $173,062.28 |
DisclosureSEC source: 0001140361-18-024271 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,733,231 Read SEC document |
| May 14, 2018 Filed May 16, 2018 21:15 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon Stock | 354,791 | $1.72 | $609,069.71 |
DisclosureSEC source: 0001140361-18-024271 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,854,525 Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 17:29 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | PurchaseCall Options · Derivative | 246 | $8.50 Strike: $60.00 | $2,091.00 |
DisclosureSEC source: 0001140361-18-018902 · doc1.xml · derivative · entry 1 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,213 Underlying: Common Stock · 24,600 shares Expires 2018-11-16 Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | PurchaseCall Options · Derivative | 967 | $7.47 Strike: $60.00 | $7,226.39 |
DisclosureSEC source: 0001140361-18-018797 · doc1.xml · derivative · entry 1 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967 Underlying: Common Stock · 96,700 shares Expires 2018-11-16 Read SEC document |
| November 13, 2017 Filed Dec 14, 2017 20:46 UTC | aTYR PHARMA INC ATYR · Entity 7233 | SaleCommon Stock | 1,083 | $3.95 | $4,277.85 |
DisclosureSEC source: 0001140361-17-046221 · doc1.xml · nonDerivative · entry 6 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,209,316 Read SEC document |
| November 10, 2017 Filed Dec 14, 2017 20:46 UTC | aTYR PHARMA INC ATYR · Entity 7233 | SaleCommon Stock | 5,860 | $4.00 | $23,444.69 |
DisclosureSEC source: 0001140361-17-046221 · doc1.xml · nonDerivative · entry 5 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,210,399 Read SEC document |
| November 09, 2017 Filed Dec 14, 2017 20:46 UTC | aTYR PHARMA INC ATYR · Entity 7233 | SaleCommon Stock | 5,819 | $4.15 | $24,151.18 |
DisclosureSEC source: 0001140361-17-046221 · doc1.xml · nonDerivative · entry 4 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,216,259 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.